Sandimmune and Mobility decreased - a phase IV clinical study of FDA data

Summary:

Mobility decreased is reported as a side effect among people who take Sandimmune (cyclosporine), especially for people who are female, 40-49 old, also take Magnevist, and have Cardiac failure.

The phase IV clinical study analyzes which people have Mobility decreased when taking Sandimmune. It is created by eHealthMe based on reports of 6,679 people who have side effects when taking Sandimmune from the FDA, and is updated regularly.

What is Sandimmune?

Sandimmune has active ingredients of cyclosporine. eHealthMe is studying from 6,694 Sandimmune users. Check the latest studies of Sandimmune.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,775 drugs and 1,632 conditions by eHealthMe. Check the latest studies of Mobility decreased.

On Jul, 17, 2026

6,679 people reported to have side effects when taking Sandimmune.
Among them, 12 people (0.18%) have Mobility decreased.

Could Sandimmune cause Mobility decreased?

Among these 12 people:

What is the gender of people who have Mobility decreased when taking Sandimmune? *

female: 75 %
male: 25 %

What is the age of people who have Mobility decreased when taking Sandimmune? *

What are other drugs people take besides Sandimmune? *

What are other side effects people have besides Mobility decreased? *

Pain: 9 people, 75.00%
General Physical Health Deterioration (weak health status): 8 people, 66.67%
Itching: 7 people, 58.33%
Skin Tightness: 7 people, 58.33%
Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 7 people, 58.33%
Injury: 6 people, 50.00%
Joint Range Of Motion Decreased (disease of joint movement): 6 people, 50.00%
Dry Skin: 6 people, 50.00%
Skin Exfoliation (removal of the oldest dead skin cells): 6 people, 50.00%
Emotional Distress: 6 people, 50.00%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 16.67%
Pain: 2 people, 16.67%
Oedema Peripheral (superficial swelling): 2 people, 16.67%
Cardiac Failure: 2 people, 16.67%
Erythrodermic Psoriasis (generalized redness of the skin): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Sandimmune and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sandimmune:

Sandimmune (6,694 reports)

Browse all side effects of Sandimmune:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mobility decreased:

Mobility decreased (1,775 drugs)

Browse all the conditions that are associated with Mobility decreased:

Mobility decreased (1,632 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on cyclosporine (the active ingredients of Sandimmune) and Sandimmune (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.